Accéder au contenu
Merck

SML3893

LCL521 dihydrochlroide

≥95% (HPLC)

Synonyme(s) :

(1R,2R)-2-N-(Tetradecanoylamino)-1-(40-nitrophenyl)-propyl-1,3-O,O-di-(N,N-dimethylamino) acetate dihydrochloride, 1,3-DMG-B13, 1,3-O,O-DMG-B13•2HCl, 1,3-di-DMG-B13, B13: (1R,2R)-2-(tetradecanoylamino)-1-(4′-nitrophenyl)-1,3-propandiol), LCL 521, LCL-521

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement



About This Item

Formule empirique (notation de Hill) :
C31H52N4O7·2HCl
Numéro CAS:
Poids moléculaire :
665.69
UNSPSC Code:
51111800
MDL number:
NACRES:
NA.21

Nom du produit

LCL521 dihydrochlroide, ≥95% (HPLC)

SMILES string

CN(C)CC(O[C@H](C1=CC=C(C=C1)[N+]([O-])=O)[C@@H](COC(CN(C)C)=O)NC(CCCCCCCCCCCCC)=O)=O.[2HCl]

assay

≥95% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

Catégories apparentées

Biochem/physiol Actions

N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 for enhanced lysosomal delivery and cellular potency.



LCL521 is the N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 (no inhibition against NCDase/ASAH2 or AlkCDase/ACER2). The DMG enables efficient and targeted B13 lysosomal delivery, resulting in enhanced cellular ACDase inhibitory potency (by 70% vs 12% in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13) and effective blockage of ceramide (Cer) to sphingosine (Sph) processing (80% vs 0% Sph level drop in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13).

Disclaimer

Hygroscopic

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Shai White-Gilbertson et al.
Journal of lipid research, 60(7), 1225-1235 (2019-04-17)
Radiation treatment failure or relapse after initial response to chemotherapy presents significant clinical challenges in cancer patients. Escape from initial courses of treatment can involve reactivation of embryonic developmental stages, with the formation of polynuclear giant cancer cells (PGCCs). This
Mladen Korbelik et al.
International journal of cancer, 139(6), 1372-1378 (2016-05-04)
Acid ceramidase has been identified as a promising target for cancer therapy. One of its most effective inhibitors, LCL521, was examined as adjuvant to photodynamic therapy (PDT) using mouse squamous cell carcinoma SCCVII model of head and neck cancer. Lethal
Shai White-Gilbertson et al.
Cancer medicine, 9(9), 3142-3152 (2020-03-07)
Polyploid giant cancer cells (PGCC) represent a poorly understood, small subpopulation of tumor cells that are increasingly being recognized for their critical role in therapy resistance, metastasis, and cancer recurrence. PGCC have the potential to generate progeny through primitive or
Rachael E Clifford et al.
Cells, 9(12) (2020-12-19)
Previous work utilizing proteomic and immunohistochemical analyses has identified that high levels of acid ceramidase (AC) expression confers a poorer response to neoadjuvant treatment in locally advanced rectal cancer. We aimed to assess the radiosensitising effect of biological and pharmacological
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase
PLoS ONE, 12(6) (2017)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique